• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Brazil·Technology·NGRD3.SA
Share

Neogrid Participações S.A. Stocks

R$ 34.1Last Updated 17.06.2026

Issuer Rating

3/7
Performance

Average

Risk

High

Recommendation

Sell

Market Cap

R$ 60.24M

R$ 34.1
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Neogrid Participações S.A., operating with its subsidiaries, delivers tailor-made software solutions globally to facilitate the comprehensive management and alignment of supply chains. Their services include the development, licensing, distribution, and deployment of these custom platforms. Additionally, the company provides specialized technical consulting and instructional programs. Its service portfolio further extends to essential functions such as software and database installation, system configuration, ongoing maintenance, and critical IT support. Neogrid serves a broad spectrum of clients, including manufacturers and retail businesses, alongside specific sectors like agribusiness, consumer packaged goods (CPG), electronics, fashion, home renovation, and the pharmaceutical and healthcare industries. Established in 1999, the firm's headquarters are situated in Joinville, Brazil.

Company Valuation

Fairly valued
4/7

From both historical and forecast perspectives, the stock is fairly priced compared to similar stocks. In particular, the stock is underpriced on P/E, of fair value on EV

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Slightly negative
3/7

The average target price of NGRD3.SA is 30 and suggests 11.9% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation to

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

18.06.2026 17:37

First Phosphate's stock soared 20%. At the G7 summit, she spoke about new deals

18.06.2026 17:08

The Anthropic Case: What New Uncertainties Will Investors Have to Deal With?

18.06.2026 16:25

Retailer Bed Bath & Beyond has announced the acquisition of a real estate brokerage. What's the logic behind this?

18.06.2026 15:50

Goldman Sachs has warned of a possible series of interest rate hikes in the U.S. as early as September

18.06.2026 15:37

Morning in New York: News Drives Volatility

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026